Why did Sharfstein bolt from the FDA?; TetraLogic closes on $23M tranche; Argen-X to partner with Lilly on antibodies

@FierceBiotech: Pfizer ups ante on Santaris RNA discovery deal with $614M pact. News | Follow @FierceBiotech

@JohnCFierce: Gotta love Novartis' new Wheresflu app to support its cold meds; hypochondriacs will LOVE it. Report | Follow @JohnCFierce

> Joshua Sharfstein's sudden departure from the FDA has triggered some intense speculation about what caused his decision to take the job of Maryland's Secretary of Health. InVivo sees it as a critical repositioning as the agency faces a resurgent Republican Party on Capitol Hill. Story

> Cancer drug developer TetraLogic Pharmaceuticals has closed the $23 million second tranche of a Series C financing completed in October 2010. TetraLogic release

> ArGEN-X BV has forged an alliance with Eli Lilly to discover and develop novel therapeutic antibody products against targets submitted by Lilly. arGen-X Release

> EyeGate Pharma, which is developing ocular therapeutics, has secured an additional $5.9 million as part of its Series D closing. With this additional tranche, Eyegate has raised a total of $28.5M in Series D funding to date. EyeGate release

> AstraZeneca has struck a deal to deploy Kinaxo's high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale. Kinaxo release

And Finally... New insights on the AMPK-SRC-2 pathway-a "critical tuning dial for controlling whole body energy"--could help pave the way to new therapies for obesity. Release

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.